Articles by Louis Garguilo

41. An All-Outsourcing Model For Orphan Drugs 6/15/2015

    Nils U. Olsson, VP of Chemistry, Manufacturing and Controls at Retrophin Inc., says his company’s business model targeting new drugs for orphan diseases allows for a perfect application of an all-outsourcing strategy. 

42. Not a Sterile Debate On Aseptic Services Crunch 5/4/2015

    Driving the aseptic services sector is positive news, but with a side effect: the breakthroughs in biologics and other increasingly complex products are enabling the creation of exciting new drugs and therapies … but all requiring the “right” capacity and “perfect" compliance at aseptic facilities.

43. Gilead Saves Lives And Healthcare Dollars By Taking Profits 4/6/2015

    It’s affordable worldwide, saves lives and healthcare dollars, allows a company to create more innovative drugs, and validates the biotech business model. Why a negative bias?

44. Profit For Good At Rottendorf Pharmaceuticals 2/10/2015

    The desire to work for a larger cause, to somehow apply whatever we do for a living to benefit society, continues to rise. And that desire can also elevate company revenues. 

45. Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance 2/5/2015

    Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.

46. Biosimilars Part 2: It's All About Dollars Now 2/2/2015

    Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.

47. Biosimilars: A Brief Manifesto of Morality And Markets 1/26/2015

    As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.

48. A Global Forum For Outsourcing (With Simple Objectives) 9/24/2014

    Perhaps the best advice I’ve heard regarding industry conferences is twofold: first, make sure you attend, and second, keep your objectives for attending simple.

49. Serial Entrepreneur Points To Initial Funding Sources For Biotechs 9/24/2014

    Kevin Judice lists himself on LinkedIn as “Entrepreneur.” Perhaps he has to; there just isn’t enough space to include the three companies he recently started and at which he concurrently is employed as CEO or CSO.

50. Sanofi-Genzyme Together On CMO Reputation Management

    Not long after Sanofi tied the knot with Genzyme in 2011, Piet Houwen was asked to lead contract-manufacturing operations. Now about 5 years into the marriage, I visit with Houwen to learn about this combination of Big Pharma and Big Bio, his role, and an attitudinal adjustment for better biologics outsourcing.